Laddar...
Radium‐223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program
BACKGROUND. In the phase III ALSYMPCA trial, metastatic castration‐resistant prostate cancer (mCRPC) patients had few prior life‐prolonging therapies. Following ALSYMPCA, which demonstrated radium‐223 survival benefit, and before radium‐223 U.S. commercial availability, an expanded access program (E...
Sparad:
| I publikationen: | Oncologist |
|---|---|
| Huvudupphovsmän: | , , , , , , , , , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
AlphaMed Press
2017
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5813754/ https://ncbi.nlm.nih.gov/pubmed/29183960 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0413 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|